CEACAM5 and neoplasm: Treatment with CEA-TCB and anti-PD-L1 blocking antibody improved anti-tumor activity compared with either agent alone; in addition, the onset of tumor regrowth was significantly delayed in the combination group compared with anti-PD-L1 single-agent treatment (Figure 4G).